Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Critical Care
Published in: Critical Care 4/2006

01-08-2006 | Review

Coagulation abnormalities in critically ill patients

Authors: Marcel Levi, Steven M Opal

Published in: Critical Care | Issue 4/2006

Login to get access

Abstract

Many critically ill patients develop hemostatic abnormalities, ranging from isolated thrombocytopenia or prolonged global clotting tests to complex defects, such as disseminated intravascular coagulation. There are many causes for a deranged coagulation in critically ill patients and each of these underlying disorders may require specific therapeutic or supportive management. In recent years, new insights into the pathogenesis and clinical management of many coagulation defects in critically ill patients have been accumulated and this knowledge is helpful in determining the optimal diagnostic and therapeutic strategy.
Appendix
Available only for authorised users
Literature
1.
Vanderschueren S, De Weerdt A, Malbrain M, Vankersschaever D, Frans E, Wilmer A, Bobbaers H: Thrombocytopenia and prognosis in intensive care. Crit Care Med 2000, 28: 1871-1876. 10.1097/00003246-200006000-00031CrossRefPubMed
2.
Baughman RP, Lower EE, Flessa HC, Tollerud DJ: Thrombocytopenia in the intensive care unit. Chest 1993, 104: 1243-1247.CrossRefPubMed
3.
Strauss R, Wehler M, Mehler K, Kreutzer D, Koebnick C, Hahn EG: Thrombocytopenia in patients in the medical intensive care unit: bleeding prevalence, transfusion requirements, and outcome. Crit Care Med 2002, 30: 1765-1771. 10.1097/00003246-200208000-00015CrossRefPubMed
4.
Stephan F, Hollande J, Richard O, Cheffi A, Maier-Redelsperger M, Flahault A: Thrombocytopenia in a surgical ICU. Chest 1999, 115: 1363-1370. 10.1378/chest.115.5.1363CrossRefPubMed
5.
Hanes SD, Quarles DA, Boucher BA: Incidence and risk factors of thrombocytopenia in critically ill trauma patients. Ann Pharmacother 1997, 31: 285-289.PubMed
6.
Akca S, Haji Michael P, de Medonca A, Suter PM, Levi M, Vincent JL: The time course of platelet counts in critically ill patients. Crit Care Med 2002, 30: 753-756. 10.1097/00003246-200204000-00005CrossRefPubMed
7.
Oppenheim-Eden A, Glantz L, Eidelman LA, Sprung CL: Spontaneous intracerebral hemorrhage in critically ill patients: incidence over six years and associated factors. Intensive Care Med 1999, 25: 63-67. 10.1007/s001340050788CrossRefPubMed
8.
Chakraverty R, Davidson S, Peggs K, Stross P, Garrard C, Littlewood TJ: The incidence and cause of coagulopathies in an intensive care population. Br J Haematol 1996, 93: 460-463. 10.1046/j.1365-2141.1996.5101050.xCrossRefPubMed
9.
MacLeod JB, Lynn M, McKenney MG, Cohn SM, Murtha M: Early coagulopathy predicts mortality in trauma. J Trauma 2003, 55: 39-44.CrossRefPubMed
10.
Shorr AF, Thomas SJ, Alkins SA, Fitzpatrick TM, Ling GS: D-dimer correlates with proinflammatory cytokine levels and outcomes in critically ill patients. Chest 2002, 121: 1262-1268. 10.1378/chest.121.4.1262CrossRefPubMed
11.
Owings JT, Gosselin RC, Anderson JT, Battistella FD, Bagley M, Larkin EC: Practical utility of the D-dimer assay for excluding thromboembolism in severely injured trauma patients. J Trauma 2001, 51: 425-429.CrossRefPubMed
12.
Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJJ: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001, 344: 699-709. 10.1056/NEJM200103083441001CrossRefPubMed
13.
Gando S, Nanzaki S, Sasaki S, Kemmotsu O: Significant correlations between tissue factor and thrombin markers in trauma and septic patients with disseminated intravascular coagulation. Thromb Haemost 1998, 79: 1111-1115.PubMed
14.
Mavrommatis AC, Theodoridis T, Orfanidou A, Roussos C, Christopoulou-Kokkinou V, Zakynthinos S: Coagulation system and platelets are fully activated in uncomplicated sepsis. Crit Care Med 2000, 28: 451-457. 10.1097/00003246-200002000-00027CrossRefPubMed
15.
Folman CC, Linthorst GE, van Mourik J, van Willigen G, de Jonge E, Levi M, de Haas M, dem Borne AE: Platelets release thrombopoietin (Tpo) upon activation: another regulatory loop in thrombocytopoiesis? Thromb Haemost 2000, 83: 923-930.PubMed
16.
Francois B, Trimoreau F, Vignon P, Fixe P, Praloran V, Gastinne H: Thrombocytopenia in the sepsis syndrome: role of hemophagocytosis and macrophage colony-stimulating factor. Am J Med 1997, 103: 114-120. 10.1016/S0002-9343(97)00136-8CrossRefPubMed
17.
Levi M, ten Cate H: Disseminated intravascular coagulation. N Engl J Med 1999, 341: 586-592. 10.1056/NEJM199908193410807CrossRefPubMed
18.
19.
Tsai HM: Platelet activation and the formation of the platelet plug: deficiency of ADAMTS13 causes thrombotic thrombocytopenic purpura. Arterioscler Thromb Vasc Biol 2003, 23: 388-396. 10.1161/01.ATV.0000058401.34021.D4CrossRefPubMed
20.
Warkentin TE, Aird WC, Rand JH: Platelet-Endothelial Interactions: Sepsis, HIT, and Antiphospholipid Syndrome. Hematology (Am Soc Hematol Educ Program) 2003, 497-519.
21.
Verma AK, Levine M, Shalansky SJ, Carter CJ, Kelton JG: Frequency of heparin-induced thrombocytopenia in critical care patients. Pharmacotherapy 2003, 23: 745-753. 10.1592/phco.23.6.745.32188CrossRefPubMed
22.
Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, Kelton JG: Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995, 332: 1330-1335. 10.1056/NEJM199505183322003CrossRefPubMed
23.
Girolami B, Prandoni P, Stefani PM, Tanduo C, Sabbion P, Eichler P, Ramon R, Baggio G, Fabris F, Girolami A: The incidence of heparin-induced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: a prospective cohort study. Blood 2003, 101: 2955-2959. 10.1182/blood-2002-07-2201CrossRefPubMed
24.
Warkentin TE: Heparin-induced thrombocytopenia: pathogenesis and management. Br J Haematol 2003, 121: 535-555. 10.1046/j.1365-2141.2003.04334.xCrossRefPubMed
25.
Cines DB, Bussel JB, McMillan RB, Zehnder JL: Congenital and acquired thrombocytopenia. Hematology (Am Soc Hematol Educ Program) 2004, 390-406.
26.
Warkentin TE: Platelet count monitoring and laboratory testing for heparin-induced thrombocytopenia. Arch Pathol Lab Med 2002, 126: 1415-1423.PubMed
27.
Greaves M, Preston FE: Approach to the bleeding patient. In Hemostasis and Thrombosis. Basic Principles and Clinical Practice. Edited by: Colman RW, Hirsh J, Marder VJ, Clowes AW, George JN. Philadelphia: Lippingcott William and Wilkins; 2001:1031-1043.
28.
Kitchen S, Preston FE: Standardization of prothrombin time for laboratory control of oral anticoagulant therapy. Semin Thromb Hemost 1999, 25: 17-25.CrossRefPubMed
29.
Bailey B, Amre DK, Gaudreault P: Fulminant hepatic failure secondary to acetaminophen poisoning: a systematic review and meta-analysis of prognostic criteria determining the need for liver transplantation. Crit Care Med 2003, 31: 299-305. 10.1097/00003246-200301000-00048CrossRefPubMed
30.
Bakhtiari K, Meijers JC, de Jonge E, Levi M: Prospective validation of the international society of thrombosis and maemostasis scoring system for disseminated intravascular coagulation. Crit Care Med 2004, 32: 2416-2421. 10.1097/01.CCM.0000147769.07699.E3CrossRefPubMed
31.
Wheeler AP, Bernard GR: Treating patients with severe sepsis. N Engl J Med 1999, 340: 207-214. 10.1056/NEJM199901213400307CrossRefPubMed
32.
Levi M, de Jonge E, Meijers J: The diagnosis of disseminated intravascular coagulation. Blood Rev 2002, 16: 217-223. 10.1016/S0268-960X(02)00032-2CrossRefPubMed
33.
Taylor FBJ, Toh CH, Hoots WK, Wada H, Levi M: Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 2001, 86: 1327-1330.PubMed
34.
Dhainaut JF, Yan SB, Joyce DE, Pettila V, Basson BR, Brandt JT, Sundin D, Levi M: Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation. J Thromb Haemost 2004, 2: 1924-1933. 10.1111/j.1538-7836.2004.00955.xCrossRefPubMed
35.
Muntean W: Coagulation and anticoagulation in extracorporeal membrane oxygenation. Artif Organs 1999, 23: 979-983. 10.1046/j.1525-1594.1999.06451.xCrossRefPubMed
36.
Rodgers RP, Levin J: A critical reappraisal of the bleeding time. Semin Thromb Hemost 1990, 16: 1-20.CrossRefPubMed
37.
Forestier F, Coiffic A, Mouton C, Ekouevi D, Chene G, Janvier G: Platelet function point-of-care tests in post-bypass cardiac surgery: are they relevant? Br J Anaesth 2002, 89: 715-721. 10.1093/bja/aef250CrossRefPubMed
38.
39.
Teufelsbauer H, Proidl S, Havel M, Vukovich T: Early activation of hemostasis during cardiopulmonary bypass: evidence for thrombin mediated hyperfibrinolysis. Thromb Haemost 1992, 68: 250-252.PubMed
40.
Hirsh J, Heddle N, Kelton JG: Treatment of heparin-induced thrombocytopenia: a critical review. Arch Intern Med 2004, 164: 361-369. 10.1001/archinte.164.4.361CrossRefPubMed
41.
42.
Mannucci PM: Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years. Blood 1997, 90: 2515-2521.PubMed
43.
Levi M, Cromheecke ME, de JE, Prins MH, de MB, Briet E, Buller HR: Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints [see comments]. Lancet 1999, 354: 1940-1947. 10.1016/S0140-6736(99)01264-7CrossRefPubMed
44.
Friederich PW, Henny CP, Messelink EJ, Geerdink MG, Keller T, Kurth KH, Buller HR, Levi M: Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind placebo-controlled randomised trial. Lancet 2003, 361: 201-205. 10.1016/S0140-6736(03)12268-4CrossRefPubMed
45.
Levi M, Peters M, Buller HR: Efficacy and safety of recombinant factor VIIa for the treatment of severe bleeding: a systematic review. Crit Care Med 2005, 33: 883-890. 10.1097/01.CCM.0000159087.85970.38CrossRefPubMed
46.
Boffard KD, Riou B, Warren B, Choong PI, Rizoli S, Rossaint R, Axelsen M, Kluger Y: Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials. J Trauma 2005, 59: 8-15.CrossRefPubMed
47.
Mayer SA, Brun NC, Begtrup K, Broderick J, Davis S, Diringer MN, Skolnick BE, Steiner T: Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2005, 352: 777-785. 10.1056/NEJMoa042991CrossRefPubMed
48.
Roberts HR: Recombinant factor VIIa (Novoseven) and the safety of treatment. Semin Hematol 2001, 38: 48-50. 10.1016/S0037-1963(01)90148-9CrossRefPubMed
49.
Abraham E, Laterre PF, Garg R, Levy H, Talwar D, Trzaskoma BL, Francois B, Guy JS, Bruckmann M, Rea-Neto A, et al.: Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 2005, 353: 1332-1341. 10.1056/NEJMoa050935CrossRefPubMed
50.
Bernard GR, Macias WL, Joyce DE, Williams MD, Bailey J, Vincent JL: Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis. Crit Care 2003, 7: 155-163. 10.1186/cc2167PubMedCentralCrossRefPubMed
51.
Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I, Chalupa P, Atherstone A, Penzes I, Kubler A, et al.: Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 2001, 286: 1869-1878. 10.1001/jama.286.15.1869CrossRefPubMed
52.
Kienast J, Juers M, Wiedermann CJ, Hoffmann JN, Ostermann H, Strauss R, Keinecke HO, Warren BL, Opal SM: Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. J Thromb Haemost 2006, 4: 90-97. 10.1111/j.1538-7836.2005.01697.xCrossRefPubMed
Metadata
Title
Coagulation abnormalities in critically ill patients
Authors
Marcel Levi
Steven M Opal
Publication date
01-08-2006
Publisher
BioMed Central
Published in
Critical Care / Issue 4/2006
Electronic ISSN: 1364-8535
DOI
https://doi.org/10.1186/cc4975

Other articles of this Issue 4/2006

Critical Care 4/2006 Go to the issue

Research

Unloading work of breathing during high-frequency oscillatory ventilation: a bench study

Commentary

Allowing for spontaneous breathing during high-frequency oscillation: the key for final success?

Research

Effects of dopexamine on the intestinal microvascular blood flow and leucocyte activation in a sepsis model in rats

Letter

Measuring extravascular lung water: animals and humans are not the same

Commentary

Measurement of PEEP-induced alveolar recruitment: just a research tool?

Commentary

Think outside the box: extrapulmonary manifestations of severe respiratory syncytial virus infection